Weight and survival were tested in people; muscle findings mostly came from mice

The brief answer: these studies tested four different problems

Weight, strength, infection deaths, and skin changes were measured separately. Some studies involved people; some involved mice or laboratory-grown cells. A mouse result leaves the question about human treatment open. The peptides were Retatrutide, MOTS-c, Thymosin Alpha-1, and GHK-Cu. Their findings don't add up to one treatment answer. Your first question is whose health the study actually tested.

Retatrutide lowered weight in human trials, with longer-term questions unresolved. MOTS-c changed muscle performance in mice, without proven human treatment benefits. The largest Thymosin Alpha-1 infection trial did not show fewer deaths. Small GHK-Cu skin studies often tested mixtures of several ingredients. Each finding needs the limits of that particular test beside it.

A changed blood test isn't always a change you can feel.

Stronger tests placed similar patients in separate treatment groups. Enough people were needed to keep unusual results from dominating. Researchers also needed to measure the health problem being claimed. Less weight, stronger muscles, and surviving illness are different measurements. Survival claims need researchers to count how many people died. Confidence grows when a different team gets a matching result.

Four checks separate a treatment effect from other changes

First: People receiving the comparison treatment show what happens without the peptide. The placebo provides comparison care while containing none of the medicine being tested. Sometimes the comparison is another medicine for the same illness. Ordinary care, passing time, and expectations can all change symptoms. A fair comparison helps show which changes came from treatment.

Feeling better afterward doesn't tell you what caused the improvement.

Second: The number of people tested affects how much chance matters. In a small study, a few unusual results can dominate. More people usually make the result less open to chance. A large group still needs a fair, carefully planned test.

Third: The health change measured sets the limit on the answer. A blood test cannot measure how far someone can walk. A cell change cannot show whether anyone survived an illness. The study must measure the benefit that is claimed.

Fourth: Tests by other researchers show whether the finding holds elsewhere. Different patients or ways of measuring may change the answer. Matching results add confidence; different results narrow what is known. The side-by-side study account explains these checks for each peptide.

The four peptides do different things in the body

Proteins and peptides contain amino acids joined to each other. Amino acids are their small chemical parts. Certain peptides carry cell messages; others hold onto metals. Others copy actions of hormones, substances that carry messages around your body. The research label groups substances with quite different medical possibilities.

Retatrutide was designed for hunger control and blood-sugar effects. MOTS-c is made inside cells and studied during energy shortages. Thymosin Alpha-1 comes from the thymus gland, which helps immune defenses develop. GHK-Cu research concerns copper attachment and possible tissue repair. Proof about one peptide cannot show another peptide's health effects.

Sharing a name for a group doesn't mean sharing a treatment.

The four peptides also differ in permission for medical use. Retatrutide is still being tested and has no medicine approval. MOTS-c has no approved treatment use in people. Some countries approve Thymosin Alpha-1 as a medicine. The United States has not approved that medicine for sale. Skin cosmetics may contain GHK-Cu under the name Copper Tripeptide-1. GHK-Cu has no approval for treatment throughout the body. Study findings do not show a treatment suited to you.

Short tests leave years of health effects unanswered

Years of treatment cannot be judged from shorter studies alone. Retatrutide trials found substantial losses of weight and liver fat. Lasting heart and kidney effects remain unanswered ^[1][3][4]. In stressed cells, MOTS-c moved into the part holding DNA. DNA holds instructions for cell growth and normal cell work. That cell finding did not prove a human treatment benefit ^[12].

A result belongs to the people or cells actually tested.

A look back at COVID-19 care suggested fewer deaths with Thymosin Alpha-1. The much larger TESTS trial did not show fewer sepsis deaths ^[13][15]. In sepsis, infection causes a dangerous reaction throughout the body. Laboratory GHK-Cu tests found changes linked to making and repairing tissue. Those tests didn't show that anyone's wound actually healed. Poor passage through skin also limits what creams might do ^[18][19].

Your health question may need a different kind of test. A survival claim needs evidence that fewer people died. A cream's cell findings need proof of changes in skin. Fair comparisons help separate treatment from chance or other care. Repeated results then help show whether the answer holds elsewhere.